Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Trial details
- Registry ID
- NCT06295731
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Hexavalent OX40 agonist antibody; Ordastobart
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)NCT06295731 | INBX | Phase 2, Phase 3 | Recruiting | 2029-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |